Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood

Autores
Aricò, Maurizio; Astigarraga, Itziar; Braier, Jorge; Donadieu, Jean; Gadner, Helmut; Glogova, Evgenia; Grois, Nicole; Henter, Jan-Inge; Janka, Gritta; McClain, Kenneth L.; Ladisch, Stephan; Pötschger, Ulrike; Rosso, Diego; Thiem, Elfriede; Weitzman, Sheila; Windebank, Kevin; Minkov, Milen; For the Histiocyte Society
Año de publicación
2014
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Skeletal involvement is generally, but not universally, characteristic of Langerhans cell histiocytosis (LCH). We investigated whether the presence of bone lesions at diagnosis is a prognostic factor for survival in LCH. Nine hundred and thirty-eight children with multisystem (MS) LCH, both high (386 RO+) and low (RO−) risk, were evaluated for bone lesions at diagnosis. Risk organ (RO+) involvement was defined as: haematopoietic system (haemoglobin <100 g/l, and/or white blood cell count <4·0 × 109/l and/or platelet count <100 × 109/l), spleen (>2 cm below the costal margin), liver (>3 cm and/or hypoproteinaemia, hypoalbuminaemia, hyperbilirubinaemia, and/or increased aspartate transaminase/alanine transaminase). Given the general view that prognosis in LCH worsens with increasing extent of disease, the surprising finding was that in MS+RO+ LCH the probability of survival with bone involvement 74 ± 3% (n = 230, 56 events) was reduced to 62 ± 4% (n = 156, 55 events) if this was absent (P = 0·007). An even greater difference was seen in the subgroup of patients with both liver and either haematopoiesis or spleen involvement: 61 ± 5% survival (n = 105; 52 events) if patients had bony lesions, versus 47 ± 5% (n = 111; 39 events) if they did not (P = 0·014). This difference was retained in multivariate analysis (P = 0·048). Although as yet unexplained, we conclude that bone involvement at diagnosis is a previously unrecognized favourable prognostic factor in MS+RO+ LCH.
Fil: Aricò, Maurizio. Azienda Sanitaria Provinciale; Italia
Fil: Astigarraga, Itziar. Bio Cruces Health Research Institute; España. Universidad del País Vasco; España
Fil: Braier, Jorge. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina
Fil: Donadieu, Jean. Hospital Trousseau; Francia
Fil: Gadner, Helmut. St. Anna Children's Hospital; Austria. Children's Cancer Research Institute; Austria
Fil: Glogova, Evgenia. St. Anna Children's Hospital; Austria. Children's Cancer Research Institute; Austria
Fil: Grois, Nicole. Children's Cancer Research Institute; Austria. St. Anna Children's Hospital; Austria
Fil: Henter, Jan-Inge. Karolinska Huddinge Hospital. Karolinska Institutet; Suecia
Fil: Janka, Gritta. University Medical Centre. Department of Haematology and Oncology; Alemania
Fil: McClain, Kenneth L.. Texas Children's Cancer and Hematology Centers ; Estados Unidos
Fil: Ladisch, Stephan. Children's National Medical Center ; Estados Unidos
Fil: Pötschger, Ulrike. St. Anna Children's Hospital; Austria. Children's Cancer Research Institute; Austria
Fil: Rosso, Diego. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños Pedro Elizalde (ex Casa Cuna); Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Thiem, Elfriede. St. Anna Children's Hospital; Austria. Children's Cancer Research Institute; Austria
Fil: Weitzman, Sheila. Hospital for Sick Children. Division of Hematology/Oncology; Canadá
Fil: Windebank, Kevin. University of Newcastle; Reino Unido
Fil: Minkov, Milen. Children's Cancer Research Institute; Austria. St. Anna Children's Hospital; Austria
Fil: For the Histiocyte Society.
Materia
Histiocytosis
Childhood
Bone Involvement
Prognostic Factor
Langerhans Cell Histiocytosis
Multsystem Disease
Bone Lesion
Risck Organ
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/15796

id CONICETDig_0d6df489069c26eea03744607843b33b
oai_identifier_str oai:ri.conicet.gov.ar:11336/15796
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhoodAricò, MaurizioAstigarraga, ItziarBraier, JorgeDonadieu, JeanGadner, HelmutGlogova, EvgeniaGrois, NicoleHenter, Jan-IngeJanka, GrittaMcClain, Kenneth L.Ladisch, StephanPötschger, UlrikeRosso, DiegoThiem, ElfriedeWeitzman, SheilaWindebank, KevinMinkov, MilenFor the Histiocyte SocietyHistiocytosisChildhoodBone InvolvementPrognostic FactorLangerhans Cell HistiocytosisMultsystem DiseaseBone LesionRisck Organhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Skeletal involvement is generally, but not universally, characteristic of Langerhans cell histiocytosis (LCH). We investigated whether the presence of bone lesions at diagnosis is a prognostic factor for survival in LCH. Nine hundred and thirty-eight children with multisystem (MS) LCH, both high (386 RO+) and low (RO−) risk, were evaluated for bone lesions at diagnosis. Risk organ (RO+) involvement was defined as: haematopoietic system (haemoglobin <100 g/l, and/or white blood cell count <4·0 × 109/l and/or platelet count <100 × 109/l), spleen (>2 cm below the costal margin), liver (>3 cm and/or hypoproteinaemia, hypoalbuminaemia, hyperbilirubinaemia, and/or increased aspartate transaminase/alanine transaminase). Given the general view that prognosis in LCH worsens with increasing extent of disease, the surprising finding was that in MS+RO+ LCH the probability of survival with bone involvement 74 ± 3% (n = 230, 56 events) was reduced to 62 ± 4% (n = 156, 55 events) if this was absent (P = 0·007). An even greater difference was seen in the subgroup of patients with both liver and either haematopoiesis or spleen involvement: 61 ± 5% survival (n = 105; 52 events) if patients had bony lesions, versus 47 ± 5% (n = 111; 39 events) if they did not (P = 0·014). This difference was retained in multivariate analysis (P = 0·048). Although as yet unexplained, we conclude that bone involvement at diagnosis is a previously unrecognized favourable prognostic factor in MS+RO+ LCH.Fil: Aricò, Maurizio. Azienda Sanitaria Provinciale; ItaliaFil: Astigarraga, Itziar. Bio Cruces Health Research Institute; España. Universidad del País Vasco; EspañaFil: Braier, Jorge. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; ArgentinaFil: Donadieu, Jean. Hospital Trousseau; FranciaFil: Gadner, Helmut. St. Anna Children's Hospital; Austria. Children's Cancer Research Institute; AustriaFil: Glogova, Evgenia. St. Anna Children's Hospital; Austria. Children's Cancer Research Institute; AustriaFil: Grois, Nicole. Children's Cancer Research Institute; Austria. St. Anna Children's Hospital; AustriaFil: Henter, Jan-Inge. Karolinska Huddinge Hospital. Karolinska Institutet; SueciaFil: Janka, Gritta. University Medical Centre. Department of Haematology and Oncology; AlemaniaFil: McClain, Kenneth L.. Texas Children's Cancer and Hematology Centers ; Estados UnidosFil: Ladisch, Stephan. Children's National Medical Center ; Estados UnidosFil: Pötschger, Ulrike. St. Anna Children's Hospital; Austria. Children's Cancer Research Institute; AustriaFil: Rosso, Diego. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños Pedro Elizalde (ex Casa Cuna); Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Thiem, Elfriede. St. Anna Children's Hospital; Austria. Children's Cancer Research Institute; AustriaFil: Weitzman, Sheila. Hospital for Sick Children. Division of Hematology/Oncology; CanadáFil: Windebank, Kevin. University of Newcastle; Reino UnidoFil: Minkov, Milen. Children's Cancer Research Institute; Austria. St. Anna Children's Hospital; AustriaFil: For the Histiocyte Society.Wiley2014-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/vnd.openxmlformats-officedocument.wordprocessingml.documentapplication/pdfhttp://hdl.handle.net/11336/15796Aricò, Maurizio; Astigarraga, Itziar; Braier, Jorge; Donadieu, Jean; Gadner, Helmut; et al.; Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood; Wiley; British Journal Of Haematology; 169; 2; 12-2014; 241-2480007-10481365-2141enginfo:eu-repo/semantics/altIdentifier/doi/10.1111/bjh.13271info:eu-repo/semantics/altIdentifier/url/http://onlinelibrary.wiley.com/doi/10.1111/bjh.13271/fullinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:52:06Zoai:ri.conicet.gov.ar:11336/15796instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:52:06.672CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood
title Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood
spellingShingle Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood
Aricò, Maurizio
Histiocytosis
Childhood
Bone Involvement
Prognostic Factor
Langerhans Cell Histiocytosis
Multsystem Disease
Bone Lesion
Risck Organ
title_short Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood
title_full Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood
title_fullStr Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood
title_full_unstemmed Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood
title_sort Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood
dc.creator.none.fl_str_mv Aricò, Maurizio
Astigarraga, Itziar
Braier, Jorge
Donadieu, Jean
Gadner, Helmut
Glogova, Evgenia
Grois, Nicole
Henter, Jan-Inge
Janka, Gritta
McClain, Kenneth L.
Ladisch, Stephan
Pötschger, Ulrike
Rosso, Diego
Thiem, Elfriede
Weitzman, Sheila
Windebank, Kevin
Minkov, Milen
For the Histiocyte Society
author Aricò, Maurizio
author_facet Aricò, Maurizio
Astigarraga, Itziar
Braier, Jorge
Donadieu, Jean
Gadner, Helmut
Glogova, Evgenia
Grois, Nicole
Henter, Jan-Inge
Janka, Gritta
McClain, Kenneth L.
Ladisch, Stephan
Pötschger, Ulrike
Rosso, Diego
Thiem, Elfriede
Weitzman, Sheila
Windebank, Kevin
Minkov, Milen
For the Histiocyte Society
author_role author
author2 Astigarraga, Itziar
Braier, Jorge
Donadieu, Jean
Gadner, Helmut
Glogova, Evgenia
Grois, Nicole
Henter, Jan-Inge
Janka, Gritta
McClain, Kenneth L.
Ladisch, Stephan
Pötschger, Ulrike
Rosso, Diego
Thiem, Elfriede
Weitzman, Sheila
Windebank, Kevin
Minkov, Milen
For the Histiocyte Society
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Histiocytosis
Childhood
Bone Involvement
Prognostic Factor
Langerhans Cell Histiocytosis
Multsystem Disease
Bone Lesion
Risck Organ
topic Histiocytosis
Childhood
Bone Involvement
Prognostic Factor
Langerhans Cell Histiocytosis
Multsystem Disease
Bone Lesion
Risck Organ
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Skeletal involvement is generally, but not universally, characteristic of Langerhans cell histiocytosis (LCH). We investigated whether the presence of bone lesions at diagnosis is a prognostic factor for survival in LCH. Nine hundred and thirty-eight children with multisystem (MS) LCH, both high (386 RO+) and low (RO−) risk, were evaluated for bone lesions at diagnosis. Risk organ (RO+) involvement was defined as: haematopoietic system (haemoglobin <100 g/l, and/or white blood cell count <4·0 × 109/l and/or platelet count <100 × 109/l), spleen (>2 cm below the costal margin), liver (>3 cm and/or hypoproteinaemia, hypoalbuminaemia, hyperbilirubinaemia, and/or increased aspartate transaminase/alanine transaminase). Given the general view that prognosis in LCH worsens with increasing extent of disease, the surprising finding was that in MS+RO+ LCH the probability of survival with bone involvement 74 ± 3% (n = 230, 56 events) was reduced to 62 ± 4% (n = 156, 55 events) if this was absent (P = 0·007). An even greater difference was seen in the subgroup of patients with both liver and either haematopoiesis or spleen involvement: 61 ± 5% survival (n = 105; 52 events) if patients had bony lesions, versus 47 ± 5% (n = 111; 39 events) if they did not (P = 0·014). This difference was retained in multivariate analysis (P = 0·048). Although as yet unexplained, we conclude that bone involvement at diagnosis is a previously unrecognized favourable prognostic factor in MS+RO+ LCH.
Fil: Aricò, Maurizio. Azienda Sanitaria Provinciale; Italia
Fil: Astigarraga, Itziar. Bio Cruces Health Research Institute; España. Universidad del País Vasco; España
Fil: Braier, Jorge. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina
Fil: Donadieu, Jean. Hospital Trousseau; Francia
Fil: Gadner, Helmut. St. Anna Children's Hospital; Austria. Children's Cancer Research Institute; Austria
Fil: Glogova, Evgenia. St. Anna Children's Hospital; Austria. Children's Cancer Research Institute; Austria
Fil: Grois, Nicole. Children's Cancer Research Institute; Austria. St. Anna Children's Hospital; Austria
Fil: Henter, Jan-Inge. Karolinska Huddinge Hospital. Karolinska Institutet; Suecia
Fil: Janka, Gritta. University Medical Centre. Department of Haematology and Oncology; Alemania
Fil: McClain, Kenneth L.. Texas Children's Cancer and Hematology Centers ; Estados Unidos
Fil: Ladisch, Stephan. Children's National Medical Center ; Estados Unidos
Fil: Pötschger, Ulrike. St. Anna Children's Hospital; Austria. Children's Cancer Research Institute; Austria
Fil: Rosso, Diego. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños Pedro Elizalde (ex Casa Cuna); Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Thiem, Elfriede. St. Anna Children's Hospital; Austria. Children's Cancer Research Institute; Austria
Fil: Weitzman, Sheila. Hospital for Sick Children. Division of Hematology/Oncology; Canadá
Fil: Windebank, Kevin. University of Newcastle; Reino Unido
Fil: Minkov, Milen. Children's Cancer Research Institute; Austria. St. Anna Children's Hospital; Austria
Fil: For the Histiocyte Society.
description Skeletal involvement is generally, but not universally, characteristic of Langerhans cell histiocytosis (LCH). We investigated whether the presence of bone lesions at diagnosis is a prognostic factor for survival in LCH. Nine hundred and thirty-eight children with multisystem (MS) LCH, both high (386 RO+) and low (RO−) risk, were evaluated for bone lesions at diagnosis. Risk organ (RO+) involvement was defined as: haematopoietic system (haemoglobin <100 g/l, and/or white blood cell count <4·0 × 109/l and/or platelet count <100 × 109/l), spleen (>2 cm below the costal margin), liver (>3 cm and/or hypoproteinaemia, hypoalbuminaemia, hyperbilirubinaemia, and/or increased aspartate transaminase/alanine transaminase). Given the general view that prognosis in LCH worsens with increasing extent of disease, the surprising finding was that in MS+RO+ LCH the probability of survival with bone involvement 74 ± 3% (n = 230, 56 events) was reduced to 62 ± 4% (n = 156, 55 events) if this was absent (P = 0·007). An even greater difference was seen in the subgroup of patients with both liver and either haematopoiesis or spleen involvement: 61 ± 5% survival (n = 105; 52 events) if patients had bony lesions, versus 47 ± 5% (n = 111; 39 events) if they did not (P = 0·014). This difference was retained in multivariate analysis (P = 0·048). Although as yet unexplained, we conclude that bone involvement at diagnosis is a previously unrecognized favourable prognostic factor in MS+RO+ LCH.
publishDate 2014
dc.date.none.fl_str_mv 2014-12
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/15796
Aricò, Maurizio; Astigarraga, Itziar; Braier, Jorge; Donadieu, Jean; Gadner, Helmut; et al.; Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood; Wiley; British Journal Of Haematology; 169; 2; 12-2014; 241-248
0007-1048
1365-2141
url http://hdl.handle.net/11336/15796
identifier_str_mv Aricò, Maurizio; Astigarraga, Itziar; Braier, Jorge; Donadieu, Jean; Gadner, Helmut; et al.; Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood; Wiley; British Journal Of Haematology; 169; 2; 12-2014; 241-248
0007-1048
1365-2141
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1111/bjh.13271
info:eu-repo/semantics/altIdentifier/url/http://onlinelibrary.wiley.com/doi/10.1111/bjh.13271/full
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/vnd.openxmlformats-officedocument.wordprocessingml.document
application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269136665706496
score 13.13397